China's Shanghai Fosun Pharmaceutical is planning a bid for German generic drugmaker Stada, already the center of a 3.6 billion euro ($3.8 billion) takeover battle between two private equity consortia, two people close to the matter said.
Fosun Pharma is also holding early-stage talks with buyout funds including CVC about a potential joint bid, but may decide initially to go it alone with a view to taking financial investors on board later, one of the people said.
Fosun Pharma said it currently had no information to disclose. Stada declined to comment.
Stada is expecting to receive so-called confirmatory bids from a consortium comprising Advent and Permira as well as from rivals Bain and Cinven, who have teamed up as well, on Friday. Final bids are due just before Easter, the sources said.